Status:

COMPLETED

Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in HD Patients(EGESTUDY)

Lead Sponsor:

Ege University

Collaborating Sponsors:

Fresenius Medical Care North America

Conditions:

End-stage Renal Disease

Hemodialysis

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

This study aims to investigate the effects of high flux dialyser use and ultra pure dialysate utilization on cardiovascular disease by evaluating cardiovascular morbidity and mortality, progression of...

Detailed Description

This proposed prospective, randomized, controlled study aims to investigate the effects of high flux dialyser use and ultra pure dialysate utilization on cardiovascular disease by evaluating cardiovas...

Eligibility Criteria

Inclusion

  • Aged between 18 and 80 years
  • On maintenance bicarbonate hemodialysis scheduled thrice weekly, at least 12 hours/week
  • Willingness to participate in the study with a written informed consent.

Exclusion

  • To be scheduled for living donor renal transplantation
  • To have serious life-limiting co-morbid situations; namely active malignancy, active infection, end-stage cardiac, pulmonary, or hepatic disease; pregnancy or lactating

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

704 Patients enrolled

Trial Details

Trial ID

NCT00295191

Start Date

November 1 2005

End Date

March 1 2010

Last Update

October 4 2011

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

FMC Clinics

Bornova, İzmir, Turkey (Türkiye), 35100

2

Ege University School of Medicine

Bornova-Izmir, Turkey (Türkiye), 35100